Stock Track | IGM Biosciences Soars After Bullish Analyst Actions

Stock Track

2024/11/11

Shares of IGM Biosciences (IGMS) surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their "Buy" ratings and increased their price targets for the stock.

RBC Capital analyst Brian Abrahams maintained a "Buy" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report released on November 8th.

Meanwhile, Stifel analyst raised the firm's price target on IGM Biosciences to $27 from $25, while keeping a "Buy" rating. The firm expressed confidence in the company's management and their plans for advancing the development of their oncology treatments.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1152914755"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152914755\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152914755?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152914755","market":"us","top_or_hot":-1,"title":"Stock Track | IGM Biosciences Soars After Bullish Analyst Actions","media":"Stock Track","content":"<p>Shares of IGM Biosciences (IGMS) surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their \"Buy\" ratings and increased their price targets for the stock.</p>\n\n<p>RBC Capital analyst Brian Abrahams maintained a \"Buy\" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report released on November 8th.</p>\n\n<p>Meanwhile, Stifel analyst raised the firm's price target on IGM Biosciences to $27 from $25, while keeping a \"Buy\" rating. The firm expressed confidence in the company's management and their plans for advancing the development of their oncology treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IGM Biosciences Soars After Bullish Analyst Actions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IGM Biosciences Soars After Bullish Analyst Actions\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-11 22:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of IGM Biosciences (IGMS) surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their \"Buy\" ratings and increased their price targets for the stock.</p>\n\n<p>RBC Capital analyst Brian Abrahams maintained a \"Buy\" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report released on November 8th.</p>\n\n<p>Meanwhile, Stifel analyst raised the firm's price target on IGM Biosciences to $27 from $25, while keeping a \"Buy\" rating. The firm expressed confidence in the company's management and their plans for advancing the development of their oncology treatments.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IGMS","symbol_name":"IGM Biosciences","start_time":0,"source_url":"","article_id":"1152914755","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152914755","pubTimestamp":1731335970,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of IGM Biosciences  surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their \"Buy\" ratings and increased their price targets for the stock.RBC Capital analyst Brian Abrahams maintained a \"Buy\" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report rele","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IGMS":"IGM Biosciences"},"translate_title":"分析师看涨行动后，IGM Biosciences股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IGMS":1},"content_text":"Shares of IGM Biosciences (IGMS) surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their \"Buy\" ratings and increased their price targets for the stock.\nRBC Capital analyst Brian Abrahams maintained a \"Buy\" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report released on November 8th.\nMeanwhile, Stifel analyst raised the firm's price target on IGM Biosciences to $27 from $25, while keeping a \"Buy\" rating. The firm expressed confidence in the company's management and their plans for advancing the development of their oncology treatments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}